New advances in antibiotic development and discovery

被引:50
作者
Alekshun, MN [1 ]
机构
[1] Paratek Pharmaceut Inc, Boston, MA 02111 USA
关键词
antibiotic development; antibiotic discovery; antibiotic resistance; beta-lactam; fluoroquinolone; glycolipodepsipeptide; ketolide; macrolide; multiple antibiotic resistance; oxazolidinone; peptide deformylase inhibitor; rifamycin; streptogramin; tetracycline;
D O I
10.1517/13543784.14.2.117
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The development of new antibiotics is crucial to controlling current and future infectious diseases caused by antibiotic-resistant bacteria. Increased development costs, the difficulty in identifying new drug classes, unanticipated drug toxicities, the ease by which bacteria develop resistance to new antibiotics and the failure of many agents to address antibiotic resistance specifically, however, have all led to an overall decline in the number of antibiotics that are being introduced into clinical practice. Although there are few, if any, advances likely in the immediate future, there are agents in both clinical and preclinical development that can address some of the concerns of the infectious disease community. Many of these antibiotics will be tailored to specific infections caused by a relatively modest number of susceptible and resistant organisms.
引用
收藏
页码:117 / 134
页数:18
相关论文
共 142 条
[1]
In vitro activity of OPT-80 against clostridium difcile [J].
Ackermann, G ;
Löffler, B ;
Adler, D ;
Rodloff, AC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2280-2282
[2]
Alekshun M.N., 2004, DRUG DISCOV TODAY TH, V1, P483
[3]
Alekshun Michael N, 2005, Expert Opin Investig Drugs, V14, P93, DOI 10.1517/13543784.14.1.93
[4]
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].
Andries, K ;
Verhasselt, P ;
Guillemont, J ;
Göhlmann, HWH ;
Neefs, JM ;
Winkler, H ;
Van Gestel, J ;
Timmerman, P ;
Zhu, M ;
Lee, E ;
Williams, P ;
de Chaffoy, D ;
Huitric, E ;
Hoffner, S ;
Cambau, E ;
Truffot-Pernot, C ;
Lounis, N ;
Jarlier, V .
SCIENCE, 2005, 307 (5707) :223-227
[5]
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine [J].
Angehrn, P ;
Buchmann, S ;
Funk, C ;
Goetschi, E ;
Gmuender, H ;
Hebeisen, P ;
Kostrewa, D ;
Link, H ;
Luebbers, T ;
Masciadri, R ;
Nielsen, J ;
Reindl, P ;
Ricklin, F ;
Schmitt-Hoffmann, A ;
Theil, FP .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (06) :1487-1513
[6]
Peptide deformylase as an antibacterial drug target:: Target validation and resistance development [J].
Apfel, CM ;
Locher, H ;
Evers, S ;
Takács, B ;
Hubschwerlen, C ;
Pirson, W ;
Page, MGP ;
Keck, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1058-1064
[7]
A new class of bacterial RNA polymerase inhibitor affects nucleotide addition [J].
Artsimovitch, I ;
Chu, C ;
Lynch, AS ;
Landick, R .
SCIENCE, 2003, 302 (5645) :650-654
[8]
Adverse drug reactions: implications for the development of fluoroquinolones [J].
Ball, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 :21-27
[9]
BATTEIGER B, 2004, 44 INT C ANT AG CHEM
[10]
Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA [J].
Bauer, G ;
Berens, C ;
Projan, SJ ;
Hillen, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (04) :592-599